Sunrest Lifescience Ltd

Sunrest Lifescie reported a consolidated net profit of 2.01 crore for the year ending March 2025, with net sales and total operating income both at 33.41 crore. The company showed growth in profitability, a strengthened balance sheet, and positive cash flow from operating activities of 1.00 crore.

As of 24-Oct, Sunrest Lifescience Ltd's stock price is Rs 42.00, down 5.62%, with significant underperformance reflected in a year-to-date decline of -18.45% and a bearish trend indicated by trading below all major moving averages. Despite this, there has been a 250% increase in delivery volume, suggesting some investor interest amidst the overall negative performance.

As of 10-Oct, Sunrest Lifescience Ltd is currently priced at 45.50, reflecting a 5.81% increase today, but has underperformed with declines over the past week, month, and year-to-date. The stock is trading below key moving averages and has seen a significant drop in investor participation, indicating a bearish trend despite today's positive movement.

As of 08-Oct, Sunrest Lifescience Ltd is priced at 43.40 with no change, having significantly underperformed with declines of 8.05% over the past week and 15.73% year-to-date. The stock is trading below all major moving averages, indicating a bearish trend, and has seen a substantial drop in investor interest.

As of 26-Sep, Sunrest Lifescience Ltd is currently priced at 47.20, reflecting a 7.27% increase today, while showing a year-to-date decline of 8.35%. Despite recent gains, the stock has underperformed over the longer term but has outperformed its sector today and gained traction relative to the market.

As of September 24, 2025, Sunrest Lifescie is fairly valued with a PE ratio of 9.44, lower than some peers but higher than others, and has underperformed the Sensex with a year-to-date return of -14.56%.

As of 24-Sep, Sunrest Lifescience Ltd is priced at 44.00 with no change, indicating a downward trend as it trades below all key moving averages. Despite a significant increase in investor participation, the stock has declined 14.48% over the past month and 14.56% year-to-date, underperforming compared to the benchmark Sensex.

As of 23-Sep, Sunrest Lifescience Ltd's stock price is Rs. 44.00, down 8.71%, marking a new 52-week low and underperforming its sector. Despite a significant decline over the past month and year, there has been increased investor interest indicated by a rise in delivery volume.

As of 22-Sep, Sunrest Lifescience Ltd's stock price is 48.20, reflecting an 8.31% increase, but it has seen a significant drop in investor participation. While it has outperformed its sector recently, its long-term performance remains weak compared to the benchmark Sensex.

As of 19-Sep, Sunrest Lifescience Ltd is priced at Rs 44.50, having declined 9.37% in the past week and 13.17% in the past month, while trading below all key moving averages. Despite a 288.89% increase in delivery volume, the stock remains close to its 52-week low, reflecting investor caution amid broader market gains.

As of 18-Sep, Sunrest Lifescience Ltd is priced at 44.30 with no change, having declined 9.78% over the past week and 16.34% over the past month, indicating significant underperformance compared to the Sensex, which has gained 1.67% in the same period. Despite increased investor interest, the stock remains below its moving averages, suggesting a bearish trend.

As of September 17, 2025, Sunrest Lifescie is considered an attractive investment due to its undervalued status reflected in a low PE ratio of 9.51, especially when compared to peers like Elitecon International and MMTC, despite its recent stock performance lagging behind the Sensex.

As of 17-Sep, Sunrest Lifescience Ltd's stock price is at 44.30, unchanged, and has underperformed its sector and the broader market significantly, declining 9.78% over the past week and 14.81% over the past month. Despite increased investor participation, the stock continues to face challenges, with a year-to-date decline of 13.98%.

As of September 16, 2025, Sunrest Lifescie is fairly valued with a PE ratio of 9.51, an EV to EBITDA of 8.29, and a ROE of 14.10%, underperforming the Sensex by 26.17% while being competitively positioned against peers like Elitecon International and Lloyds Enterprises.

As of 16-Sep, Sunrest Lifescience Ltd is priced at 44.30, showing a significant decline of 26.17% over the past year, despite a slight outperformance against its sector today. The stock is trading below all major moving averages, indicating a bearish trend, but there is increased investor interest with a 288.89% rise in delivery volume compared to the 5-day average.

As of September 15, 2025, Sunrest Lifescie is considered undervalued with an attractive valuation grade, a PE ratio of 9.66, and significant growth potential, especially compared to peers like Elitecon International and Lloyds Enterprises, despite a year-to-date stock decline of 13.98%.

As of 15-Sep, Sunrest Lifescience Ltd's stock price is Rs. 44.30, down 9.78% and at a new 52-week low, underperforming its sector and major moving averages. The stock has declined 13.98% year-to-date and 31.21% year-on-year, contrasting with the Sensex's positive performance.

As of 12-Sep, Sunrest Lifescience Ltd is priced at 49.10, with no change and significant underperformance over various periods, including a 23.76% decline in the past year. The stock is trading below all key moving averages and has seen a notable drop in investor participation, contrasting with the positive performance of the Sensex.

As of 11-Sep, Sunrest Lifescience Ltd is priced at 49.10, with no change and a bearish trend indicated by declines in both short-term performance and moving averages. The stock has underperformed compared to the benchmark Sensex, which has shown positive returns over the same periods.